- Home
- LFST vs VCEL Comparison
LFST vs VCEL Comparison
Compare LFST & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFST | VCEL |
|---|---|---|
| Founded | 2015 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2021 | 1997 |
Fundamental Metrics
Financial Performance| Metric | LFST | VCEL |
|---|---|---|
| Price | $6.45 | $36.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $9.00 | ★ $60.40 |
| AVG Volume (30 Days) | ★ 2.0M | 558.3K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 236.54 |
| EPS | N/A | ★ 0.25 |
| Revenue | ★ $1,367,570,000.00 | $258,716,999.00 |
| Revenue This Year | $15.75 | $17.86 |
| Revenue Next Year | $14.36 | $18.55 |
| P/E Ratio | ★ N/A | $147.23 |
| Revenue Growth | 13.39 | ★ 14.05 |
| 52 Week Low | $3.74 | $29.24 |
| 52 Week High | $8.30 | $63.00 |
Technical Indicators
Market Signals| Indicator | LFST | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 61.94 | 43.46 |
| Support Level | $6.26 | $37.28 |
| Resistance Level | $6.64 | $42.68 |
| Average True Range (ATR) | 0.20 | 1.78 |
| MACD | -0.03 | -0.55 |
| Stochastic Oscillator | 66.63 | 6.89 |
Price Performance
Historical ComparisonAbout LFST LifeStance Health Group Inc.
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. The group y has a single operating and reportable segment of mental health services.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.